



OPEN ACCESS

APPROVED BY

Giuseppe Giaccone,
Amgen, United States

*CORRESPONDENCE

Frontiers Editorial Office

✉ research.integrity@frontiersin.org

RECEIVED 29 August 2023

ACCEPTED 29 August 2023

PUBLISHED 04 September 2023

CITATION

Frontiers Editorial Office (2023)
Retraction: CAR-NK Cell: a new
paradigm in tumor immunotherapy.
Front. Oncol. 13:1285219.
doi: 10.3389/fonc.2023.1285219

COPYRIGHT

© 2023 Frontiers Editorial Office. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Retraction: CAR-NK Cell: a new paradigm in tumor immunotherapy

Frontiers Editorial Office*

A Retraction of the Review Article

CAR-NK Cell: a new paradigm in tumor immunotherapy

by Marofi F, Al-Awad AS, Sulaiman Rahman H, Markov A, Abdelbasset WK, Ivanovna Enina Y, Mahmoodi M, Hassanzadeh A, Yazdanifar M, Stanley Chartrand M and Jarahian M (2021). *Front. Oncol.* 11:673276. doi: 10.3389/fonc.2021.673276

The journal retracts the 2021 article cited above.

Following publication, concerns were raised regarding the contributions of the authors of the article. Our investigation, conducted in accordance with Frontiers policies, confirmed a serious breach of our authorship policies and of publication ethics; the article is therefore retracted.

This retraction was approved by the Chief Editors of Frontiers in Oncology and the Chief Executive Editor of Frontiers. The authors do not agree to this retraction.